Metabolic (bariatric) surgery is an effective long-term intervention for obesity-related T2DM, while modern injectable pharmacotherapies, including glucagon-like peptide-1 receptor agonists, have become increasingly popular. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.